Dyer J P, Featherstone J M, Solomon L Z, Crook T J, Cooper A J, Malone P S
Department of Urology, Southampton University Hospitals NHS Trust, Tremona Road, Southampton, SO16 6YD, UK.
Pediatr Surg Int. 2005 Jul;21(7):521-6. doi: 10.1007/s00383-005-1440-7. Epub 2005 Apr 28.
The intestinal element of enterocystoplasty is affected by chronic inflammatory changes, which lead to excess mucus production, urinary tract infections, and stone formation. There is also an increased risk of malignancy. These inflammatory changes may be due to diversion colitis, which affects colonic segments excluded from the faecal stream and likewise may respond to intraluminal short-chain fatty acid (SCFA) therapy. The SCFAs have interesting antiproliferative, differentiating, and pro-apoptotic effects, which are protective against colorectal cancer and may influence the risk of malignancy in enterocystoplasty. Before intravesical therapy can be considered, the effect on normal urothelium must be investigated. Primary urothelial cells cultured from biopsy specimens and transformed urothelial (RT112 and MGH-U1) and intestinal cell lines (HT29 and CaCo-2) were incubated with SCFAs. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to measure the residual viable biomass to assess cell proliferation. Proliferation of primary and transformed urothelial cells in culture was inhibited by all SCFAs in a similar time- and dose-dependent manner. The concentration of SCFA required to inhibit growth of primary cells by 50% (IC50) was 20 mM of butyrate, 120 mM of propionate, and 240 mM of acetate after incubation for 1 h. After 72 h the IC50 was 2 mM of butyrate, 4 mM of propionate, and 20 mM of acetate. Transformed urothelial and colon cancer cell lines demonstrated similar growth inhibition. Butyrate was the most potent inhibitor of cell proliferation, followed by propionate and then acetate. Growth inhibition is not an immediate cytotoxic effect, and urothelial cells show a degree of adaptation to butyrate and growth recovery after incubation with butyrate. In conclusion, butyrate- and propionate-induced growth inhibition is potentially clinically significant and may have therapeutically beneficial implications in vivo.
肠膀胱扩大术的肠道部分会受到慢性炎症变化的影响,这会导致黏液分泌过多、尿路感染和结石形成。恶性肿瘤风险也会增加。这些炎症变化可能是由于改道性结肠炎引起的,它会影响被排除在粪便流之外的结肠段,同样也可能对肠腔内短链脂肪酸(SCFA)治疗有反应。短链脂肪酸具有有趣的抗增殖、分化和促凋亡作用,对结直肠癌有保护作用,可能会影响肠膀胱扩大术的恶性肿瘤风险。在考虑膀胱内治疗之前,必须研究其对正常尿路上皮的影响。将从活检标本培养的原代尿路上皮细胞、转化尿路上皮细胞(RT112和MGH-U1)以及肠道细胞系(HT29和CaCo-2)与短链脂肪酸一起孵育。采用3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐(MTT)法测量残余活细胞量以评估细胞增殖。所有短链脂肪酸均以类似的时间和剂量依赖性方式抑制培养中原代和转化尿路上皮细胞的增殖。孵育1小时后,抑制原代细胞生长50%(IC50)所需的短链脂肪酸浓度为:丁酸20 mM、丙酸120 mM、乙酸240 mM。72小时后,IC50分别为:丁酸2 mM、丙酸4 mM、乙酸20 mM。转化尿路上皮细胞系和结肠癌细胞系表现出类似的生长抑制。丁酸是最有效的细胞增殖抑制剂,其次是丙酸,然后是乙酸。生长抑制不是即时的细胞毒性作用,尿路上皮细胞对丁酸有一定程度的适应性,与丁酸孵育后会出现生长恢复。总之,丁酸和丙酸诱导的生长抑制可能具有临床意义,并且在体内可能具有治疗有益作用。